Scinai Immunotherapeutics Stock (NASDAQ:SCNI)

Ownership Financials Chart Transcripts

Previous Close

$2.84

52W Range

$2.23 - $8.92

50D Avg

$3.54

200D Avg

$4.09

Market Cap

$2.30M

Avg Vol (3M)

$27.28K

Beta

2.46

Div Yield

-

SCNI Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

IL

Employees

31

IPO Date

May 11, 2015

Website

SCNI Performance

SCNI Financial Summary

	Dec 22	Dec 21	Dec 20
Revenue	-	-	-
Operating Income	$-11.06M	$-34.83M	$2.28M
Net Income	$-5.80M	$-39.98M	$-1.39M
EBITDA	$-10.50M	$-32.44M	$3.48M
Basic EPS	$-3.07	$-28.32	$-1.25
Diluted EPS	$-3.07	$-28.32	$-1.25

Fiscal year ends in Dec 22 | Currency in USD

Latest Earnings Call Transcripts

Q2 24Aug 20, 24 | 2:28 PM